sankai/iStock via Getty Images Corporate FRNs pay floating coupons tied to short-term rates plus a credit spread, offering higher yields with minimal interest rate sensitivity. T-bills are short, zero-coupon Treasuries. Key Takeaways: Corporate FRNs offer yield that resets with short-term rates. T-bills are the safest short-term cash with zero-coupon Treasuries with high liquidity and minimal cred...
sankai/iStock via Getty Images Corporate FRNs pay floating coupons tied to short-term rates plus a credit spread, offering higher yields with minimal interest rate sensitivity. T-bills are short, zero-coupon Treasuries. Key Takeaways: Corporate FRNs offer yield that resets with short-term rates. T-bills are the safest short-term cash with zero-coupon Treasuries with high liquidity and minimal credit risk. What Is a Floating Rate Note (FRN)? A corporate floating rate note (FRN) pays a coupon which resets periodically based on a short-term reference rate (typically SOFR) plus a fixed credit spread, causing income to rise when short-term rates increase and decline when rates fall. Because these coupons adjust regularly, FRN prices have minimal sensitivity to interest rate movements, unlike fixed-rate bonds, making income the primary source of returns over time. Who Should Invest in FRNs? Corporate floating rate notes may be appropriate for investors seeking an enhanced yield versus risk-free rates with minimal interest rate risk. Because FRN coupons reset with prevailing reference rates, they can be particularly useful in environments where rates are elevated, volatile, or uncertain, and where traditional fixed rate bonds face price pressure from rising yields. FRNs can also function as a cash complement for investors with intermediate holding periods who are willing to accept modest volatility in exchange for higher income potential than money market instruments or Treasury bills. While corporate FRN prices tend to be stable due to low duration, returns are still influenced by credit spreads, meaning short-term volatility is possible during periods of market stress. What Is a T-Bill? Treasury bills (T-bills) are short-term U.S. government securities issued with maturities from a few days up to 52 weeks. T-bills are sold at a discount to par and pay par at maturity, they are zero-coupon instruments. Who Should Invest in T-Bills? Investors needing the safest, most liqui...
An Israeli court has rejected an appeal to allow a five-year-old Palestinian boy with an aggressive form of cancer to enter Israel for life-saving treatment, citing a government policy that bars residents registered in Gaza from crossing the border, even when they no longer live there. In a ruling issued on Sunday, the Jerusalem district court dismissed a petition seeking permission to transfer th...
An Israeli court has rejected an appeal to allow a five-year-old Palestinian boy with an aggressive form of cancer to enter Israel for life-saving treatment, citing a government policy that bars residents registered in Gaza from crossing the border, even when they no longer live there. In a ruling issued on Sunday, the Jerusalem district court dismissed a petition seeking permission to transfer the child from Ramallah to Tel Hashomer hospital near Tel Aviv for a bone marrow transplant – a procedure unavailable in either Gaza or the occupied West Bank. The boy has been in the West Bank since 2022 where he was receiving medical care unavailable in the Gaza Strip. His doctors have determined that he urgently requires antibody immunotherapy. The decision reflects Israel’s sweeping ban on the entry of people living in Gaza after the Hamas attacks of 7 October 2023, including cancer patients who, before the war, had routinely been granted access to life-saving treatment in Jerusalem. “I have lost my last hope,” the child’s mother told Haaretz, describing the ruling as a death sentence for her son. She said the boy’s father died of cancer three years ago. In his judgment, the Israeli judge Ram Winograd characterised the petition as an indirect challenge to the security establishment’s post-7 October restrictions, which have prevented Gaza residents from entering Israel for medical treatment. While acknowledging that thousands of children in Gaza are in urgent need of care, the judge argued there was no meaningful distinction between the boy’s case and those of other patients barred by the policy. “The petitioners failed to demonstrate a real and relevant difference,” Winograd wrote, noting that the child’s presence in Ramallah did not, in his view, justify an exemption from the blanket ban. Gisha, an Israeli human rights organisation, has been engaged in legal proceedings regarding the boy’s case since November 2025, arguing that the child’s situation exposed the cruelty o...
Hiroshi Watanabe/DigitalVision via Getty Images Overview I last covered Anavex Life Sciences ( AVXL ) in November. That was when Anavex was awaiting a decision from EU regulatory authorities regarding its lead drug candidate, blarcamesine, for the treatment of mild Alzheimer's disease (AD). I noted that the EU review escalated its application to Day 180, which ordinarily indicates outstanding issu...
Hiroshi Watanabe/DigitalVision via Getty Images Overview I last covered Anavex Life Sciences ( AVXL ) in November. That was when Anavex was awaiting a decision from EU regulatory authorities regarding its lead drug candidate, blarcamesine, for the treatment of mild Alzheimer's disease (AD). I noted that the EU review escalated its application to Day 180, which ordinarily indicates outstanding issues. I thought this lowered the odds of a positive opinion. Furthermore, I also pointed out that activities outside of Blarcamesine in AD were limited. For instance, recent Phase 2 schizophrenia data for ANAVEX3-71 was devoid of data on typical efficacy outcomes-like negative or positive symptoms, hallucinations, and so on. I felt that the lack of portfolio diversity left Anavex particularly vulnerable to negative developments on the blarcamesine in the AD front, leaving me bearish ("Strong Sell") on its stock ahead of the EU decision. A month later, the European Medicines Agency, or EMA, recommended the refusal of blarcamesine in AD, prompting Anavex to request a re-examination. Data by YCharts The article that follows details the company's next moves. Negative Opinion The EMA's negative opinion featured a multitude of problems with blarcamesine's application for conditional approval that makes a quick resolution challenging to envision. For starters, regulators noted that the "main study failed to demonstrate the effectiveness and safety of blarcamesine in patients with early Alzheimer's disease who do not have a mutation in the SIGMAR1 gene." Regulators also raised concerns over "methodological issues" that complicated the "validity of the results." Regarding safety, regulators highlighted "a high proportion of patients stopped treatment during the main study, mainly due to side effects related to the central nervous system, which raised concerns about how well the medicine is tolerated." Finally, regulators even expressed some concerns over quality. Concerning quality, t...
↘️ BP (UK:BP, BP): The global energy company suspended its quarterly share buyback and stepped up plans to cut costs. Shares dropped 5% in London. ↗️ TSMC (TW:2330, TSM): The world's largest contract chip maker posted its highest monthly revenue ever.
↘️ BP (UK:BP, BP): The global energy company suspended its quarterly share buyback and stepped up plans to cut costs. Shares dropped 5% in London. ↗️ TSMC (TW:2330, TSM): The world's largest contract chip maker posted its highest monthly revenue ever.
↘️ BP (UK:BP, BP): The global energy company suspended its quarterly share buyback and stepped up plans to cut costs. Shares dropped 4% in London. ↗️ TSMC (TW:2330, TSM): The world's largest contract chip maker posted its highest monthly revenue ever.
↘️ BP (UK:BP, BP): The global energy company suspended its quarterly share buyback and stepped up plans to cut costs. Shares dropped 4% in London. ↗️ TSMC (TW:2330, TSM): The world's largest contract chip maker posted its highest monthly revenue ever.
These are two of the best stocks to profit from this emerging industry. Quantum computing is an early-stage technology that carries risks but also offers great long-term rewards for investors who get in early. This technology promises to accelerate computing power, potentially leading to significant scientific breakthroughs, but over time, the use cases could be numerous. McKinsey estimates the qu...
These are two of the best stocks to profit from this emerging industry. Quantum computing is an early-stage technology that carries risks but also offers great long-term rewards for investors who get in early. This technology promises to accelerate computing power, potentially leading to significant scientific breakthroughs, but over time, the use cases could be numerous. McKinsey estimates the quantum computing market could be valued at $1 trillion or more in the next decade. Here are two stocks that could benefit from this growth. IonQ IonQ (IONQ +1.40%) is one of the best pure-play stocks to buy in the quantum computing market. It has been investing in this technology for over 20 years. The company says its Tempo computing system offers a computational space that is 36 quadrillion times larger than competitors, but the most telling sign of its potential is its revenue growth. It is focused on commercializing its quantum computers through cloud partners and other enterprise agreements. It's still early, but so far it is seeing significant progress, with revenue growing 222% year over year in the third quarter. The consensus estimate has revenue reaching $192 million in the current fiscal year before increasing to $316 million next year. Expand NYSE : IONQ IonQ Today's Change ( 1.40 %) $ 0.49 Current Price $ 35.48 Key Data Points Market Cap $13B Day's Range $ 33.66 - $ 35.64 52wk Range $ 17.88 - $ 84.64 Volume 66K Avg Vol 21M Gross Margin -747.41 % IonQ has the benefit of growing off a small base to deliver explosive returns to investors, but this also comes with risks. The relatively low amount of revenue underscores the technology's early-stage nature and the need for patience. This is a volatile stock, currently down 58% from its recent peak amid a broad sell-off in tech stocks. It's also expensive, trading at a sales multiple of 109. Investors will need to watch for steady technical progress in developing its quantum computing systems, including reducing error ...
The AI frenzy is now coming for CPUs, as a new Reuters report says both Intel and AMD are struggling to meet enterprise demand, resulting in surge in prices. Server CPUs are now under immense demand from hyperscalers, potentially forcing Intel/AMD to shift away from client products. Over the past few quarters, DRAM, NAND, and semiconductors are experiencing massive shortages. This has ultimately c...
The AI frenzy is now coming for CPUs, as a new Reuters report says both Intel and AMD are struggling to meet enterprise demand, resulting in surge in prices. Server CPUs are now under immense demand from hyperscalers, potentially forcing Intel/AMD to shift away from client products. Over the past few quarters, DRAM, NAND, and semiconductors are experiencing massive shortages. This has ultimately created an adverse impact not just on consumers alone, but also on manufacturers like Intel and AMD. According to a new report by Reuters, Intel's server CPU products in China are seeing extensive price hikes, as the demand from professional markets has made delivery lead times extend over six months. The report further mentions that apart from Intel, AMD is also facing similar supply constraints as well, given that the company does depend on TSMC for its EPYC lineup of processors, and since the Taiwan chip giant currently caters to the demand of the entire AI supply chain, the manufacturing times have significantly increased in the past few weeks. Interestingly, Intel's CEO, Lip-Bu Tan, discussed this situation during the Q4 earnings call, where it was revealed that Team Blue failed to meet hyperscaler demand due to supply constraints on server CPUs. This situation is another trouble for gamers out there, given that several hyperscalers are in the process of replacing older server equipment, which involves upgrading to newer x86 architectures, and this is driving a whole new wave of demand in the server CPU segment. Similar to what is seen with consumer GPUs, it's fair to say that both Intel and AMD will prioritize fulfilling enterprise demand over the client segment, which could mean CPUs are in short supply and drive prices in the retail market.
TLDR Oracle stock surged 9.6% Monday after D.A. Davidson upgraded shares to Buy from Neutral with a $180 price target. OpenAI has around $40 billion cash on hand and may raise another $100 billion by end of quarter to pay for Oracle’s data center buildout. Oracle took in roughly $800 million in revenue from TikTok USA last year and now holds a 15% stake in the new entity. The stock has dropped 55%...
TLDR Oracle stock surged 9.6% Monday after D.A. Davidson upgraded shares to Buy from Neutral with a $180 price target. OpenAI has around $40 billion cash on hand and may raise another $100 billion by end of quarter to pay for Oracle’s data center buildout. Oracle took in roughly $800 million in revenue from TikTok USA last year and now holds a 15% stake in the new entity. The stock has dropped 55% from its September record high of $328.33, now trading at $155.95. Oracle carries $130 billion in debt and $248 billion in operating-lease commitments that will weigh on finances for years. 💥 Find the Next KnockoutStock! Get live prices, charts, and KO Scores from KnockoutStocks.com , the data-driven platform ranking every stock by quality and breakout potential. Oracle stock posted its best single-day gain since September on Monday. Shares climbed 9.6% to $155.95. Oracle Corporation, ORCL The rally came after D.A. Davidson analyst Gil Luria upgraded the stock to Buy from Neutral. He maintained his $180 price target. The upgrade centered on OpenAI’s improved financial position. Luria believes the AI company’s strengthened funding runway removes a major concern for Oracle investors. “We believe OpenAI already has as much as $40B of cash on hand and may be raising as much as another $100B by the end of the quarter,” Luria wrote. This money should help pay for the data centers Oracle is building for OpenAI. The market had been valuing Oracle’s OpenAI relationship negatively. Luria sees the potential fundraise as a catalyst for the stock to outperform. Oracle’s shares are down 55% from their September record high of $328.33. That peak came after the company announced over $300 billion in new contract obligations. The excitement faded when investors learned a single OpenAI contract accounted for most of that backlog. OpenAI doesn’t turn a profit. OpenAI Partnership Takes Center Stage D.A. Davidson now views OpenAI’s ability to pay Oracle more optimistically. The AI startup coul...
Another trillion-dollar stock has become the apple of billionaires' eyes. For much of the last three decades, investors have had a game-changing technology or hyped trend to capture their attention and capital. Some of these popular trends include the advent and proliferation of the internet, genome decoding, nanotechnology, 3D printing, blockchain technology, cannabis, and the metaverse. But on r...
Another trillion-dollar stock has become the apple of billionaires' eyes. For much of the last three decades, investors have had a game-changing technology or hyped trend to capture their attention and capital. Some of these popular trends include the advent and proliferation of the internet, genome decoding, nanotechnology, 3D printing, blockchain technology, cannabis, and the metaverse. But on rare occasions, two growth-altering trends have coexisted. Right now, investors are privy to the evolution of artificial intelligence (AI) and the rise of quantum computing. Both technologies offer tantalizing addressable opportunities. Analysts at PwC foresee AI adding over $15 trillion to the global economy by 2030. Meanwhile, Boston Consulting Group believes specialized quantum computers can create between $450 billion and $850 billion in worldwide economic value come 2040. These are high-ceiling figures that can yield a laundry list of winners. While Wall Street's largest publicly traded company, Nvidia (NVDA +2.50%), is a logical choice to continue leading the AI revolution and spur advancements in quantum computing, there's another trillion-dollar stock that billionaire money managers would rather own. Nvidia has set the stage, but may be priced for perfection Nvidia's claim to fame is, undoubtedly, its AI hardware. The company's several generations of graphics processing units (GPUs) account for an overwhelming share of the GPUs currently deployed in enterprise data centers. While nothing is guaranteed in the tech space, Nvidia's spot atop the GPU pedestal appears safe for the foreseeable future. No external competitors have been able to rival the compute capabilities of Hopper (H100), Blackwell, or Blackwell Ultra. When coupled with persistent AI-GPU scarcity, it's easy to see why Nvidia has been able to charge a substantial premium for its hardware. Nvidia CEO Jensen Huang is also making life challenging for its rivals. Huang is overseeing the introduction of an adv...
Key Points Artificial intelligence (AI) and quantum computing offer tantalizing addressable markets that can lead to a long list of winners. Billionaire money managers have been paring down their stake in the face of the AI revolution, Nvidia -- and profit-taking may not tell the entire story. Meanwhile, several billionaires have piled into a trillion-dollar company that's ideally positioned to be...
Key Points Artificial intelligence (AI) and quantum computing offer tantalizing addressable markets that can lead to a long list of winners. Billionaire money managers have been paring down their stake in the face of the AI revolution, Nvidia -- and profit-taking may not tell the entire story. Meanwhile, several billionaires have piled into a trillion-dollar company that's ideally positioned to benefit from the rise of AI and the advent of quantum computing. 10 stocks we like better than Alphabet › For much of the last three decades, investors have had a game-changing technology or hyped trend to capture their attention and capital. Some of these popular trends include the advent and proliferation of the internet, genome decoding, nanotechnology, 3D printing, blockchain technology, cannabis, and the metaverse. But on rare occasions, two growth-altering trends have coexisted. Right now, investors are privy to the evolution of artificial intelligence (AI) and the rise of quantum computing. Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » Both technologies offer tantalizing addressable opportunities. Analysts at PwC foresee AI adding over $15 trillion to the global economy by 2030. Meanwhile, Boston Consulting Group believes specialized quantum computers can create between $450 billion and $850 billion in worldwide economic value come 2040. These are high-ceiling figures that can yield a laundry list of winners. While Wall Street's largest publicly traded company, Nvidia (NASDAQ: NVDA), is a logical choice to continue leading the AI revolution and spur advancements in quantum computing, there's another trillion-dollar stock that billionaire money managers would rather own. Nvidia has set the stage, but may be priced for perfection Nvidia's claim to fame is, undoubtedly, its AI hardware. The company's ...
The chief executive of Barclays has said he is “deeply dismayed and shocked” at the “depravity and the corruption” revealed in the Epstein files, as the bank deals with the fallout of its ex-boss Jes Staley’s ties to the convicted child sex offender. In his first public comments on the matter since the US Department of Justice began publishing documents related to Jeffrey Epstein in December, CS V...
The chief executive of Barclays has said he is “deeply dismayed and shocked” at the “depravity and the corruption” revealed in the Epstein files, as the bank deals with the fallout of its ex-boss Jes Staley’s ties to the convicted child sex offender. In his first public comments on the matter since the US Department of Justice began publishing documents related to Jeffrey Epstein in December, CS Venkatakrishnan said his thoughts went out to the victims of Epstein, who died in jail in 2019 while awaiting child sex trafficking charges. “I’m very, very deeply dismayed and shocked by the moral depravity and the corruption that you’re reading about in the latest set of instalments. You know, my heart really goes out to victims of this scandal and these crimes,” he said. However, the Barclays boss – speaking as the bank reported annual profits – stopped short of commenting directly on allegations against his predecessor, Staley. The Guardian reported last week that, in 2019, US prosecutors reviewed allegations of rape and bodily harm against Staley, including that he forced a woman to touch his genitals during a massage before raping her, and left “bloody marks” on the arms of a woman he called “Tinkerbell”. There is no evidence that prosecutors decided to pursue the allegations. Staley, who has previously denied any wrongdoing, has not responded to the Guardian’s requests for comment made over several months, either directly or via his lawyers. He has never been charged with a crime related to the allegations. During a UK court hearing in 2025, Staley admitted to having sex with a member of Epstein’s staff in New York, but agreed with a lawyer during cross-examination that he would describe the intercourse as “consensual”. When Venkatakrishnan was asked whether the allegations outlined in the Epstein files had prompted any further internal reviews at Barclays, the bank’s head of media said: “We have nothing further to add on that point.” It comes as the bank and its chai...
primeimages/E+ via Getty Images Market Environment U.S. equities ended the fourth quarter on a firm footing, with the S&P 500 Index returning 2.7%, extending the steady grind upward that characterized 2025, after the tariff announcements. Investor confidence was supported by a familiar trio: corporate earnings that came in better than expected, a Federal Reserve (Fed) that pushed further into an e...
primeimages/E+ via Getty Images Market Environment U.S. equities ended the fourth quarter on a firm footing, with the S&P 500 Index returning 2.7%, extending the steady grind upward that characterized 2025, after the tariff announcements. Investor confidence was supported by a familiar trio: corporate earnings that came in better than expected, a Federal Reserve (Fed) that pushed further into an easing stance, and a macroeconomic backdrop that — despite mounting cross-currents — remained resilient in the aggregate. Market sentiment also benefited from improving clarity on trade policy, including an extension of the U.S. – China truce and selective tariff relief aimed at easing consumer affordability pressures. At the same time, the quarter was defined by widening dispersion beneath the index-level surface. The market’s biggest tailwind — continued investment tied to artificial intelligence (AI) — was increasingly accompanied by scrutiny around AI infrastructure bottlenecks, sources of financing, and whether the AI theme could deliver returns commensurate with the capital deployed. Macroeconomic risks also remained in play: labor market softening became harder to ignore, consumers appeared more cautious and bifurcated across income cohorts, and housing stayed under pressure. Complicating the read-through, a prolonged government shutdown reduced economic data visibility, amplifying debate over inflation and employment signals just as global central bank dynamics leaned less uniformly supportive. Nevertheless, U.S. equities reinforced a constructive baseline for the S&P 500 Index, where Health Care was the top performing sector, while Real Estate was the weakest. During the quarter, we continued to observe secular themes that we believe are creating attractive investment opportunities—corporations are digitizing their operations, cloud computing is growing and supporting innovation, and AI is at an inflection point, potentially enabling significant increases in product...
(RTTNews) - Indian shares eked out modest gains on Tuesday, with underlying sentiment helped by firm global cues, foreign institutional investor (FII) buying and continued optimism over the India-U.S. interim trade deal. Days after India and the U.S. announced the framework for an Interim Agreement regarding reciprocal and mutually beneficial trade, the White House has issued a fact sheet highligh...
(RTTNews) - Indian shares eked out modest gains on Tuesday, with underlying sentiment helped by firm global cues, foreign institutional investor (FII) buying and continued optimism over the India-U.S. interim trade deal. Days after India and the U.S. announced the framework for an Interim Agreement regarding reciprocal and mutually beneficial trade, the White House has issued a fact sheet highlighting key terms of the agreement. Rather than a finalized pact, the document describes a set of commitments and steps that the U.S. and Indian governments say they will begin implementing in the coming weeks. The benchmark BSE Sensex rose by 208.17 points, or 0.25 percent, to 84,273.92, extending its rally into a third consecutive session. The broader NSE Nifty index ended up 67.85 points, or 0.26 percent, at 25,935.15 amid the weekly expiry of options contracts. The BSE mid-cap and small-cap indexes edged up by 0.2 percent and half a percent, respectively. The market breadth was strong on the BSE, with 2,602 shares rising while 1,642 shares declined and 163 shares closed unchanged. Eternal soared 5.2 percent and Tata Steel surged 2.9 percent while Tech Mahindra, Power Grid Corp and Mahindra & Mahindra all rose around 2 percent. Lumax, a key player in the auto component and sector, soared 20 percent after the company reported robust Q3 earnings. Likewise, stock exchange operator BSE surged 6.3 percent on strong Q3 results, with net profit climbing 172 percent year-on-year. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.